Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
3 November 2009
Orciprenaline sulphate (Alupent Syrup) is a medicine used to treat airway obstruction seen in conditions such as asthma. A review of orciprenaline sulphate recently conducted by the MHRA showed that the balance of its benefits and risks is no longer favourable. Therefore, this medicine will be withdrawn from the market over the next year.
The following Public Assessment Report (published November 2009) presents a summary of the data and conclusions from the orciprenaline review.
Download the Public Assessment Report
(269Kb).
Read the November Drug Safety Update for further information.
